What is it about?
In clinical practice, treatment timing of multi-targeted kinase inhibitors for the patients with radioiodine refractory differentiated thyroid cancer (RAIR-DTC) is one of the important clinical questions. In this post-hoc analysis of a phase III trial (SELECT), we explore whether baseline tumor burden may predict treatment outcomes and help considering introduction of lenvatinib for RAIR-DTC patients
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Higher baseline tumor burden predicted worse survival outcomes. although lenvatinib showed high response rate irrespective of tumor size. The cut-off level of 40 mm in sum of the diameters may help considering optimal timing of lenvatinib for RAIR-DTC patients.
Perspectives
In the era of cancer genomic medicine, there is still role of multi-targeted kinase inhibitors for RAIR-DTC. Hence, it is important to use all of the available treatment options for these patients.
Naomi Kiyota
Kobe University Hospital
Read the Original
This page is a summary of: Impact of baseline tumor burden on overall survival in patients with radioiodine‐refractory differentiated thyroid cancer treated with lenvatinib in the SELECT global phase 3 trial, Cancer, April 2022, Wiley,
DOI: 10.1002/cncr.34181.
You can read the full text:
Resources
Contributors
The following have contributed to this page
